The long-term study of a new medicine (galegenimab) in people with a type of eye disease (geographic atrophy secondary to age-related macular degeneration)

A Study Assessing the Long-Term Safety and Tolerability of RG6147 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Eye Disorder
Macular Degeneration
Age-Related Macular Degeneration
Dry Macular Degeneration
Geographic Atrophy

Results
Download

Study results

LPS GR42558 Final Results February 2024 USA English (PDF, 0.2 MB)

LPS GR42558 Final Results February 2024 USA Spanish (PDF, 0.2 MB)

What is Clinical Research?

In clinical research, volunteers, researchers, and medical professionals work together toward a shared goal: better treatment outcomes for patients. Clinical trials are vital to their process. They are carefully designed and follow approved protocols.

The long-term study of a new medicine (galegenimab) in people with a type of eye disease (geographic atrophy secondary to age-related macular degeneration)

Study results

LPS GR42558 Final Results February 2024 USA English (PDF, 0.2 MB)

LPS GR42558 Final Results February 2024 USA Spanish (PDF, 0.2 MB)

What is Clinical Research?

For the latest version of this information please go to www.forpatients.roche.com

External Site

Directly contact Roche for questions

Contact the hospital directly

You are about to leave ForPatients

Thank you

Request a call back

Find participating medical centers and current study status in each of them

The long-term study of a new medicine (galegenimab) in people with a type of eye disease (geographic atrophy secondary to age-related macular degeneration)

For the latest version of this information please go to www.forpatients.roche.com